摘要
表皮生长因子受体基因在肿瘤细胞中通过点突变、扩增或缺失实现其蛋白功能的变化和调节其相关分子靶向药物的反应性。本文着重介绍了包括非小细胞肺癌、头颈部鳞癌、结直肠癌、胰腺癌、肝胆系统肿瘤、食管癌和胃癌、乳腺癌和卵巢癌、神经胶质瘤等多种肿瘤组织中表皮生长因子受体基因酪氨酸激酶区的突变状态及与分子靶向药物治疗相关的临床意义。
Epidermal growth factor receptor （EGFR） performs the change of protein function and modulates the reactivity of its receptor-targeted drugs by its gene point mutation, amplification or deletion in tumor cells. This article focuses on EGFR tyrosine kinase gene mutation status as well as its clinical significance in multiple tumors including non- small cell lung cancer, head- and- neck squamous carcinoma, colorectal carcinoma, pancreatic adenocarcinoma, hepatobiliary cancers, esophageal cancer, gastric cancer, breast cancer, ovarian cancer and glioblastoma.
出处
《中国全科医学》
CAS
CSCD
2008年第13期1197-1201,共5页
Chinese General Practice
关键词
表皮生长因子受体
基因突变
肿瘤
Epidermal growth factor receptor
Gene mutation
Tumor
